HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma.
Gynecopathology
HER2
Immunohistochemistry
Ovarian cancer
Ovarian clear cell carcinoma
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
05
06
2023
accepted:
30
08
2023
revised:
21
07
2023
medline:
30
10
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
ppublish
Résumé
Ovarian clear cell carcinoma (OCCC) is a subtype of ovarian carcinoma characterized by unique biological features and highly malignant characteristics including low chemosensitivity. Therefore, new therapeutic targets are needed. These could include the downstream pathways of receptor tyrosine kinases, especially the human epidermal growth factor receptor 2 (HER2). Our main objective was to characterize the HER2 status using immunohistochemistry (IHC) and FISH on 118 OCCCs, also considering the novel paradigm of HER2-zero and HER2-low status. Other aims included determination of the association between HER2 status and survival, HER2 gene DNA and RNA NGS analysis, HER2 gene expression analysis, and correlation between IHC and gene expression in HER2-zero and HER2-low cases. Cases with HER2 overexpression/amplification accounted for 5.1% (6/118), with additional 3% harbouring HER2 gene mutation. The remaining 112 (94.9%) cases were HER2-negative. Of these, 75% were classified as HER2-zero and 25% as HER2-low. This percentage of HER2 aberrations is significant concerning their possible therapeutic influence. Cases from the HER2-zero group showed significantly better survival. Although this relationship lost statistical significance in multivariate analysis, the results have potential therapeutic significance. HER2 gene expression analysis showed a significant correlation with HER2 IHC status in the entire cohort (HER2-positive vs. HER2-negative), while in the cohort of only HER2-negative cases, the results did not reach statistical significance, suggesting that gene expression analysis would not be suitable to confirm the subdivision into HER2-low and HER2-zero. Our results also emphasize the need for standardized HER2 testing in OCCC to determine the best predictor of clinical response.
Identifiants
pubmed: 37676270
doi: 10.1007/s00428-023-03640-4
pii: 10.1007/s00428-023-03640-4
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
497-507Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : RVO VFN 64165
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : AZV NV19-03-00007
Organisme : lékařská fakulta Univerzity Karlovy
ID : UNCE204065
Organisme : lékařská fakulta Univerzity Karlovy
ID : SVV260631
Organisme : European Regional Development Fund
ID : EF16_013/0001674
Organisme : BBMRI_CZ
ID : LM2023033
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Almstedt K, Heimes AS, Kappenberg F, Battista MJ, Lehr HA, Krajnak S, Lebrecht A, Gehrmann M, Stewen K, Brenner W, Weikel W, Rahnenfuhrer J, Hengstler JG, Hasenburg A, Schmidt M (2022) Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. Eur J Cancer 173:10–19. https://doi.org/10.1016/j.ejca.2022.06.012
doi: 10.1016/j.ejca.2022.06.012
pubmed: 35839597
Amano T, Chano T, Yoshino F, Kimura F, Murakami T (2019) Current position of the molecular therapeutic targets for ovarian clear cell carcinoma: a literature review. Healthcare (Basel) 7(3):94. https://doi.org/10.3390/healthcare7030094
doi: 10.3390/healthcare7030094
pubmed: 31366141
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-X
doi: 10.1016/S0140-6736(10)61121-X
pubmed: 20728210
Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35:446–464. https://doi.org/10.1200/JCO.2016.69.4836
doi: 10.1200/JCO.2016.69.4836
pubmed: 28129524
Bolton KL, Chen D, Corona de la Fuente RI, Fu Z, Murali R, Kobel M, Tazi Y, Cunningham JM, Chan ICC, Wiley BJ, Moukarzel LA, Winham SJ, Armasu SM, Lester J, Elishaev E, Laslavic A, Kennedy CJ, Piskorz A, Sekowska M, Brand AH, Chiew YE, Pharoah P, Elias KM, Drapkin R, Churchman M, Gourley C, DeFazio A, Karlan B, Brenton JD, Weigelt B, Anglesio MS, Huntsman D, Gayther SA, Konner J, Modugno F, Lawrenson K, Goode EL, Papaemmanuil E (2022) Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-3817
doi: 10.1158/1078-0432.CCR-21-3817
pubmed: 35816189
pmcid: 9983778
Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283–290. https://doi.org/10.1200/JCO.2003.10.104
doi: 10.1200/JCO.2003.10.104
pubmed: 12525520
Dundr P, Bártů M, Bosse T, Bui QH, Cibula D, Drozenová J, Fabian P, Fadare O, Hausnerová J, Hojný J, Hájková N, Jakša R, Laco J, Lax SF, Matěj R, Méhes G, Michálková R, Šafanda A, Němejcová K, Singh N, Stolnicu S, Švajdler M, Zima T, Stružinská I, McCluggage WG (2023) Primary mucinous tumors of the ovary: an interobserver reproducibility and detailed molecular study reveals significant overlap between diagnostic categories. Mod Pathol 36:100040. https://doi.org/10.1016/j.modpat.2022.100040
doi: 10.1016/j.modpat.2022.100040
pubmed: 36788074
Early Breast Cancer Trialists’ Collaborative g (2021) Trastuzumab for early-stage, HER2-positive breast cancer a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol 22:1139–1150. https://doi.org/10.1016/S1470-2045(21)00288-6
doi: 10.1016/S1470-2045(21)00288-6
Eiger D, Agostinetto E, Saúde-Conde R, de Azambuja E (2021) The exciting new field of HER2-low breast cancer treatment. Cancers (Basel) 13(5):1015. https://doi.org/10.3390/cancers13051015
doi: 10.3390/cancers13051015
pubmed: 33804398
Fadare O, Parkash V (2019) Pathology of endometrioid and clear cell carcinoma of the ovary. Surg Pathol Clin 12:529–564. https://doi.org/10.1016/j.path.2019.01.009
doi: 10.1016/j.path.2019.01.009
pubmed: 31097114
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O’Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD (2020) Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 26:3928–3935. https://doi.org/10.1158/1078-0432.CCR-20-0953
doi: 10.1158/1078-0432.CCR-20-0953
pubmed: 32601075
pmcid: 8792803
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O’Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD (2018) Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2neu. J Clin Oncol 36:2044–2051. https://doi.org/10.1200/JCO.2017.76.5966
doi: 10.1200/JCO.2017.76.5966
pubmed: 29584549
Fujimura M, Katsumata N, Tsuda H, Uchi N, Miyazaki S, Hidaka T, Sakai M, Saito S (2002) HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res 93:1250–1257. https://doi.org/10.1111/j.1349-7006.2002.tb01231.x
doi: 10.1111/j.1349-7006.2002.tb01231.x
pubmed: 12460467
pmcid: 5926901
Gounaris I, Brenton JD (2015) Molecular pathogenesis of ovarian clear cell carcinoma. Future Oncol 11:1389–1405. https://doi.org/10.2217/fon.15.45
doi: 10.2217/fon.15.45
pubmed: 25952785
Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A, Kawaguchi R, Tanase Y, Yoshida S, Kobayashi H (2011) Molecular genetics and epidemiology of epithelial ovarian cancer (review). Oncol Rep 26:1347–1356. https://doi.org/10.3892/or.2011.1456
doi: 10.3892/or.2011.1456
pubmed: 21922146
Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Norgaard-Pedersen B, Hogdall CK (2003) Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98:66–73. https://doi.org/10.1002/cncr.11476
doi: 10.1002/cncr.11476
pubmed: 12833457
Hoopmann M, Sachse K, Valter MM, Becker M, Neumann R, Ortmann M, Gohring UJ, Thomas A, Mallmann P, Schondorf T (2010) Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. Eur J Cancer Care (Engl) 19:809–815. https://doi.org/10.1111/j.1365-2354.2009.01112.x
doi: 10.1111/j.1365-2354.2009.01112.x
pubmed: 20105224
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189–194. https://doi.org/10.1038/nature25475
doi: 10.1038/nature25475
pubmed: 29420467
pmcid: 5808581
Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SKL, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M, Exte NETSG (2016) Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17:367–377. https://doi.org/10.1016/S1470-2045(15)00551-3
doi: 10.1016/S1470-2045(15)00551-3
pubmed: 26874901
Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J, Sumer SO, Kundra R, Razavi P, Li BT, Reales DN, Socci ND, Jayakumaran G, Zehir A, Benayed R, Arcila ME, Chandarlapaty S, Ladanyi M, Schultz N, Baselga J, Berger MF, Rosen N, Solit DB, Hyman DM, Taylor BS (2018) Accelerating discovery of functional mutant alleles in cancer. Cancer Discov 8:174–183. https://doi.org/10.1158/2159-8290.CD-17-0321
doi: 10.1158/2159-8290.CD-17-0321
pubmed: 29247016
Chuang J, Klempner S, Waters K, Atkins K, Chao J, Cho M, Hendifar A, Gangi A, Burch M, Mehta P, Gong J (2022) Therapeutic advances and challenges in the management of HER2-positive gastroesophageal cancers. Diseases 10(2):23. https://doi.org/10.3390/diseases10020023
doi: 10.3390/diseases10020023
pubmed: 35645244
pmcid: 9149813
Itamochi H, Kigawa J, Terakawa N (2008) Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 99:653–658. https://doi.org/10.1111/j.1349-7006.2008.00747.x
doi: 10.1111/j.1349-7006.2008.00747.x
pubmed: 18377417
Itamochi H, Oishi T, Oumi N, Takeuchi S, Yoshihara K, Mikami M, Yaegashi N, Terao Y, Takehara K, Ushijima K, Watari H, Aoki D, Kimura T, Nakamura T, Yokoyama Y, Kigawa J, Sugiyama T (2017) Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. Br J Cancer 117:717–724. https://doi.org/10.1038/bjc.2017.228
doi: 10.1038/bjc.2017.228
pubmed: 28728166
pmcid: 5572180
Iwamoto H, Fukasawa H, Honda T, Hirata S, Hoshi K (2003) HER-2/neu expression in ovarian clear cell carcinomas. Int J Gynecol Cancer 13:28–31. https://doi.org/10.1046/j.1525-1438.2003.13028.x
doi: 10.1046/j.1525-1438.2003.13028.x
pubmed: 12631216
Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, Jacobs SA, Bertotti A, Bose R (2015) HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 5:832–841. https://doi.org/10.1158/2159-8290.CD-14-1211
doi: 10.1158/2159-8290.CD-14-1211
pubmed: 26243863
pmcid: 4527087
Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB, Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency VBC (2010) Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29:203–211. https://doi.org/10.1097/PGP.0b013e3181c042b6
doi: 10.1097/PGP.0b013e3181c042b6
pubmed: 20407318
Koopman T, Louwen M, Hage M, Smits MM, Imholz AL (2015) Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma. Am J Clin Pathol 143:257–264. https://doi.org/10.1309/AJCPCX69HGDDGYCQ
doi: 10.1309/AJCPCX69HGDDGYCQ
pubmed: 25596252
Koopman T, Smits MM, Louwen M, Hage M, Boot H, Imholz AL (2015) HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol 141:1343–1351. https://doi.org/10.1007/s00432-014-1900-3
doi: 10.1007/s00432-014-1900-3
pubmed: 25544671
Koopman T, van der Vegt B, Dijkstra M, Bart J, Duiker E, Wisman GBA, de Bock GH, Hollema H (2018) HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation. Histopathology 73:852–863. https://doi.org/10.1111/his.13704
doi: 10.1111/his.13704
pubmed: 29989198
Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, Coukos G, Powell DJ Jr (2012) Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One 7:e49829. https://doi.org/10.1371/journal.pone.0049829
doi: 10.1371/journal.pone.0049829
pubmed: 23189165
pmcid: 3506636
Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB (2005) Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 24:147–152. https://doi.org/10.1097/01.pgp.0000152026.39268.57
doi: 10.1097/01.pgp.0000152026.39268.57
pubmed: 15782071
Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Perol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Janne PA, Investigators DE-LT (2022) Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 386:241–251. https://doi.org/10.1056/NEJMoa2112431
doi: 10.1056/NEJMoa2112431
pubmed: 34534430
Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X (2017) Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res 10:9. https://doi.org/10.1186/s13048-017-0304-9
doi: 10.1186/s13048-017-0304-9
pubmed: 28187748
pmcid: 5303290
Maru Y, Tanaka N, Ohira M, Itami M, Hippo Y, Nagase H (2017) Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. Gynecol Oncol 144:377–383. https://doi.org/10.1016/j.ygyno.2016.11.045
doi: 10.1016/j.ygyno.2016.11.045
pubmed: 27939411
Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Porra F, Conte P, Guarneri V, Dieci MV (2022) HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer 8:66. https://doi.org/10.1038/s41523-022-00434-w
doi: 10.1038/s41523-022-00434-w
pubmed: 35595761
pmcid: 9122970
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA, Investigators DE-BT (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9–20. https://doi.org/10.1056/NEJMoa2203690
doi: 10.1056/NEJMoa2203690
pubmed: 35665782
pmcid: 10561652
Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S (2020) Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol 38:1887–1896. https://doi.org/10.1200/JCO.19.02318
doi: 10.1200/JCO.19.02318
pubmed: 32058843
pmcid: 7280051
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I, Investigators DE-B (2020) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382:610–621. https://doi.org/10.1056/NEJMoa1914510
doi: 10.1056/NEJMoa1914510
pubmed: 31825192
Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S (2018) Actionable activating oncogenic ERBB2/HER2 transmembrane and juxtamembrane domain mutations. Cancer Cell 34:792-806 e795. https://doi.org/10.1016/j.ccell.2018.09.010
doi: 10.1016/j.ccell.2018.09.010
pubmed: 30449325
pmcid: 6248889
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant Trial Study T (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672. https://doi.org/10.1056/NEJMoa052306
doi: 10.1056/NEJMoa052306
pubmed: 16236737
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684. https://doi.org/10.1056/NEJMoa052122
doi: 10.1056/NEJMoa052122
pubmed: 16236738
Ross JS, Yang F, Kallakury BV, Sheehan CE, Ambros RA, Muraca PJ (1999) HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol 111:311–316. https://doi.org/10.1093/ajcp/111.3.311
doi: 10.1093/ajcp/111.3.311
pubmed: 10078105
Shibuya Y, Tokunaga H, Saito S, Shimokawa K, Katsuoka F, Bin L, Kojima K, Nagasaki M, Yamamoto M, Yaegashi N, Yasuda J (2018) Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. Genes Chromosomes Cancer 57:51–60. https://doi.org/10.1002/gcc.22507
doi: 10.1002/gcc.22507
pubmed: 29044863
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792. https://doi.org/10.1056/NEJM200103153441101
doi: 10.1056/NEJM200103153441101
pubmed: 11248153
Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ, team Hs (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36. https://doi.org/10.1016/S0140-6736(07)60028-2
doi: 10.1016/S0140-6736(07)60028-2
pubmed: 17208639
Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584–2589
doi: 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5
pubmed: 10861437
Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D (2016) Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG trial. J Clin Oncol 34:2881–2887. https://doi.org/10.1200/JCO.2016.66.9010
doi: 10.1200/JCO.2016.66.9010
pubmed: 27400948
Talia KL, Banet N, Buza N (2023) The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. Pathology 55:8–18. https://doi.org/10.1016/j.pathol.2022.11.004
doi: 10.1016/j.pathol.2022.11.004
pubmed: 36503635
Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, Thomas K, Natrajan R, Savage K, Fenwick K, Williams A, Jameson C, El-Bahrawy M, Gore ME, Gabra H, Kaye SB, Ashworth A, Reis-Filho JS (2011) Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 17:1521–1534. https://doi.org/10.1158/1078-0432.CCR-10-1688
doi: 10.1158/1078-0432.CCR-10-1688
pubmed: 21411445
Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, Watanabe A, Ochiai K, Yasuda M, Tanaka T (2004) Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol Oncol 94:735–739. https://doi.org/10.1016/j.ygyno.2004.05.055
doi: 10.1016/j.ygyno.2004.05.055
pubmed: 15350366
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med 142:1364–1382. https://doi.org/10.5858/arpa.2018-0902-SA
doi: 10.5858/arpa.2018-0902-SA
pubmed: 29846104
Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B (2004) Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol 95:570–575. https://doi.org/10.1016/j.ygyno.2004.08.043
doi: 10.1016/j.ygyno.2004.08.043
pubmed: 15581965
Yamagami W, Nagase S, Takahashi F, Ino K, Hachisuga T, Aoki D, Katabuchi H (2017) Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol 28:e32. https://doi.org/10.3802/jgo.2017.28.e32
doi: 10.3802/jgo.2017.28.e32
pubmed: 28198168
pmcid: 5323288
Yoshida K, Yoshikawa N, Shirakawa A, Niimi K, Suzuki S, Kajiyama H, Kikkawa F (2019) Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma. J Gynecol Oncol 30:e85. https://doi.org/10.3802/jgo.2019.30.e85
doi: 10.3802/jgo.2019.30.e85
pubmed: 31576683
pmcid: 6779610
Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J (2013) Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 23:25–33. https://doi.org/10.1097/IGC.0b013e3182788466
doi: 10.1097/IGC.0b013e3182788466
pubmed: 23221605